This study investigates emergency department visits for violence-related injuries occurring at home and outside the home in Cardiff, Wales, before and after COVID-19 lockdown measures were instituted in March 2020.

As long ago as in the issue of this Journal for Oct. 13,1894, the promising merits of Ian Maclaren, the now popular story-teller, were recognized. We there spoke of Maclaren’s “A General Practitioner,” as “a classic of its kind,” although it was far from being in classic dress at that time; it was then to be found only in a penny paper of London, called the British Weekly. Since that time, the features of the Highland country doctor, Dr. Weelum MacLure, have been made known all the world round in the “Bonnie Brier Bush” stories. And his physiognomy is everywhere recognized as that of one of the sturdiest and noblest medical characters that have ever appeared in fiction. If there is anywhere in fiction a more worthy, admirable and attractive personage than Dr. MacLure of Drumtochty, we will be thankful to have him pointed out to us. As his portrait has not, so far as we know, been seen in any medical gallery, we will here give space to a sketch taken from the earliest publication by Maclaren:

The importance of access to health care and the financial protections that insurance should provide have never been more salient, and the potential consequences of the costs and gaps within the patchwork system in the US have never been more dire. Would the US population be better off with a simple, single-payer, uniform Medicare-for-all type of insurance plan?

This JAMA Insights Clinical Update reviews the differential diagnosis, patterns, evaluation, and management of the most common causes of nonscarring hair loss, including male pattern balding, telogen effluvium, and alopecia areata.

Listen to the JAMA Editor’s Audio Summary for an overview and discussion of the important articles appearing in this week’s issue of JAMA.

All hand sanitizers from Mexico are under an FDA import alert to protect consumers from potentially dangerous products.

The FDA has approved a treatment regimen that will allow some patients with HIV infection to trade their daily pills for a once-a-month injection.

Two recently finalized rules provide tobacco product manufacturers with additional information on federal requirements they must meet to get their products on the market. Then-FDA Commissioner Stephen Hahn, MD, said finalization of the rules “is an important milestone in the FDA’s regulation of tobacco products.”

Acute lymphoblastic leukemia (ALL), the most common childhood cancer, is a highly curable disease, with approximately 85% of patients being long-term survivors when treated with current chemotherapy regimens. Risk-adapted, intensified chemotherapy regimens have greatly improved the outcome for children, adolescents, and young adults with newly diagnosed B-cell ALL (B-ALL), which comprises approximately 20% of patients with ALL, and can be safely delivered with proper supportive care measures. Intensification of chemotherapy as salvage therapy, frequently adopting the same agents used during initial therapy, has also been successful at inducing sustained remissions for patients with late relapses. However, this approach has been largely unsuccessful for high-risk patients who experience relapse within 3 years from diagnosis because survival outcomes for these patients remain poor. Additionally, mortality associated with toxicity related to therapy contributes significantly to the poor survival.

JAMA Live Highlights features comments from livestream interviews by JAMA Network Editor in Chief Howard Bauchner, MD. His discussions with experts in clinical care, public health, and health policy focus on critical issues related to the coronavirus disease 2019 (COVID-19) pandemic. Comments have been edited for clarity.

This Medical News article discusses reports of myocardial injury and myocarditis among patients with COVID-19.

This JAMA Patient Page describes how the new Pfizer and Moderna COVID-19 vaccines available in the US work and explains why 2 doses of these vaccines are needed to confer adequate immunity.

This cohort study estimates the association of use of intravenous immunoglobulins (IVIG) plus methylprednisolone vs IVIG alone with treatment failure for multisystem inflammatory syndrome in children (MIS-C), defined as fever persistence at 2 days or fever recurrence within 7 days.

Over the past 2 weeks numerous states have announced a major shift in coronavirus disease 2019 (COVID-19) vaccination programs—from a textured approach that includes individual risk factors for morbidity and mortality (eg, age and high-risk medical conditions), occupational risk factors for exposure (eg, first responders and correctional officers), and other societal priorities (eg, essential workers such as teachers, grocery store employees, and public transportation workers) to an approach focused on vaccinating all individuals aged 65 years and older. Concerns have been raised that the more detailed approach has been difficult to implement, thus slowing the rollout of vaccines, and may leave decisions regarding who gets vaccinated to people not adequately trained to make such a decision.

This Viewpoint reviews circulating SARS-CoV-2 genetic variants and mechanisms of immunity by which they might escape coronavirus vaccine-induced protection and proposes 6 measures to address them, including enhanced variant isolation and testing procedures and continued adherence to mask-wearing and other established public health measures.

This Viewpoint from the CDC summarizes global data about SARS-CoV-2 outbreaks at K-12 schools and emphasizes implementation of community- and school-based policies shown to diminish spread of infection that would allow safer resumption of in-person education in the 2021/22 school year.

This study uses national survey data to describe overall and regional trends in adherence to protective behaviors (mask wearing, physical distancing, staying at home, others) among US adults during the COVID-19 pandemic from April to November 2020.

This Viewpoint considers whether the shift away from private investment toward government funding of drug and vaccine development and commercialization during the coronavirus disease 2019 (COVID-19) pandemic is sustainable, arguing that the same or greater level of public investment will be necessary if drug prices are to remain affordable and if the US wants to maintain its global leadership position.

This Medical Letter review summarizes the evidence underlying the US Food and Drug Administration’s emergency use authorization of bamlanivimab, an investigational neutralizing IgG1 monoclonal antibody for treatment of COVID-19, including specification of high-risk patient groups eligible for the drug and its dosage and administration.

After stakeholders secured lower prices for a recently approved pediatric HIV medication, an international partnership has urged low- and middle-income countries to procure the drug and make it widely available.